EP300 and cancer: These include CoREST involvement in the development of cancer cell resistance to other chemotherapeutics, particularly anthracyclines, the contribution of this repressive complex to modulate other cancer-promoting gene expressions during chemotherapy, and the applicability of the above-described CoREST-p53-EP300 interdependence to p53-mutated tumors.